Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters

被引：85

作者：

Brauch, Hiltrud ^{[1
,2
]}

Schroth, Werner ^{[1
,2
]}

Goetz, Matthew P. ^{[3
]}

Muerdter, Thomas E. ^{[1
,2
]}

Winter, Stefan ^{[1
,2
]}

Ingle, James N. ^{[3
]}

Schwab, Matthias ^{[1
,2
,4
]}

Eichelbaum, Michel ^{[1
,2
]}

机构：

[1] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany

[2] Univ Tubingen, Tubingen, Germany

[3] Mayo Clin, Rochester, MN USA

[4] Univ Tubingen Hosp, Inst Expt & Clin Pharmacol & Toxicol, Tubingen, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 02期

关键词：

GROUP; 1-98; TRIAL; METABOLITE PLASMA-CONCENTRATIONS; REUPTAKE INHIBITOR PAROXETINE; ESTROGEN-RECEPTOR; ACTIVE METABOLITE; RE CYP2D6; ADJUVANT TAMOXIFEN; UGT2B7; GENOTYPE; WOMEN; POLYMORPHISMS;

D O I：

10.1200/JCO.2012.44.6625

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：176 / 180

页数：5

共 36 条

[21] Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma [J].

Muerdter, T. E. ;

Schroth, W. ;

Bacchus-Gerybadze, L. ;

Winter, S. ;

Heinkele, G. ;

Simon, W. ;

Fasching, P. A. ;

Fehm, T. ;

Eichelbaum, M. ;

Schwab, M. ;

Brauch, H. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (05) :708-717

[22] Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial [J].

Nakamura, Yusuke ;

Ratain, Mark J. ;

Cox, Nancy J. ;

Mcleod, Howard L. ;

Kroetz, Deanna L. ;

Flockhart, David A. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (16) :1264-1264

[23]

PharmGKB, WELL KNOWN PHARM ASS

[24] Re: CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women With Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial and Re: CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients [J].

Pharoah, Paul D. P. ;

Abraham, Jean ;

Caldas, Carlos .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (16) :1263-1264

[25]

Rae J M., J Natl Cancer Inst

[26] CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients [J].

Rae, James M. ;

Drury, Suzy ;

Hayes, Daniel F. ;

Stearns, Vered ;

Thibert, Jacklyn N. ;

Haynes, Ben P. ;

Salter, Janine ;

Sestak, Ivana ;

Cuzick, Jack ;

Dowsett, Mitch .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06) :452-460

[27] Personalized Tamoxifen: What Is the Best Way Forward? [J].

Rae, James M. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) :3206-3208

[28]

Ratliff B, 2004, J NATL CANCER I, V96, P883, DOI 10.1093/jnci/djh170

[29]

Regan M M., J Natl Cancer Inst

[30] CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial [J].

Regan, Meredith M. ;

Leyland-Jones, Brian ;

Bouzyk, Mark ;

Pagani, Olivia ;

Tang, Weining ;

Kammler, Roswitha ;

Dell'Orto, Patrizia ;

Biasi, Maria Olivia ;

Thuerlimann, Beat ;

Lyng, Maria B. ;

Ditzel, Henrik J. ;

Neven, Patrick ;

Debled, Marc ;

Maibach, Rudolf ;

Price, Karen N. ;

Gelber, Richard D. ;

Coates, Alan S. ;

Goldhirsch, Aron ;

Rae, James M. ;

Viale, Giuseppe .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (06) :441-451

← 1 2 3 4 →